OpenLB
Open Library of Bioscience
Advanced Search
Journal of biomedical materials research. Part B, Applied biomaterials
06, 2021;109 (6): 864-876.

A high molecular weight hyaluronic acid biphasic dispersion as potential therapeutics for interstitial cystitis.

Peadar R Rooney, Vijaya Krishna Kannala, Niranjan G Kotla, Ana Benito, Damien Dupin, Iraida Loinaz, Leo R Quinlan, Yury Rochev, Abhay Pandit
Author Information
  1. Peadar R Rooney: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
  2. Vijaya Krishna Kannala: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
  3. Niranjan G Kotla: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
  4. Ana Benito: CIDETEC, Parque Científicoy Tecnológico de Gipuzkoa, San Sebastián, Spain.
  5. Damien Dupin: CIDETEC, Parque Científicoy Tecnológico de Gipuzkoa, San Sebastián, Spain.
  6. Iraida Loinaz: CIDETEC, Parque Científicoy Tecnológico de Gipuzkoa, San Sebastián, Spain.
  7. Leo R Quinlan: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
  8. Yury Rochev: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
  9. Abhay Pandit: CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
PMID: 33103826 DOI: 10.1002/jbm.b.34751

Abstract

interstitial cystitis (IC) is a progressive bladder disease characterized by increased urothelial permeability, inflammation of the bladder with abdominal pain. While there is no consensus on the etiology of the disease, it was believed that restoring the barrier between urinary solutes and (GAG) urothelium would interrupt the progression of this disease. Currently, several treatment options include intravesical delivery of hyaluronic acid (HA) and/or chondroitin sulfate solutions, through a catheter to restore the urothelial barrier, but have shown limited success in preclinical, clinical trials. Herein we report for the first time successful engineering and characterization of biphasic system developed by combining cross-linked hyaluronic acid and naïve HA solution to decrease inflammation and permeability in an in vitro model of interstitial cystitis. The cross-linking of HA was performed by 4-arm-polyethyeleneamine chemistry. The HA formulations were tested for their viscoelastic properties and the effects on cell metabolism, inflammatory markers, and permeability. Our study demonstrates the therapeutic effects of different ratios of the biphasic system and reports their ability to increase the barrier effect by decreasing the permeability and alteration of cell metabolism with respect to relative controls. Restoring the barrier by using biphasic system of HA therapy may be a promising approach to IC.

Keywords

barrier effect hyaluronic acid inflammation interstitial cystitis permeability

References

  1. Carbohydr Polym. 2016 Oct 20;151:576-583 [PMID: 27474602]
  2. Biosci Biotechnol Biochem. 2008 Apr;72(4):1111-4 [PMID: 18391466]
  3. Cell Physiol Biochem. 2016;39(4):1618-25 [PMID: 27627755]
  4. J Urol. 2005 Jul;174(1):344-9 [PMID: 15947687]
  5. Int J Urol. 2014 Apr;21 Suppl 1:34-41 [PMID: 24807491]
  6. Int Urogynecol J. 2012 Sep;23(9):1193-9 [PMID: 21904840]
  7. Biomaterials. 2008 Feb;29(4):438-47 [PMID: 17959242]
  8. FEBS Lett. 1997 Nov 17;417(3):307-10 [PMID: 9409739]
  9. Biotechnol Lett. 2010 Jun;32(6):733-42 [PMID: 20155383]
  10. J Tissue Eng. 2017 Sep 06;8:2041731417726464 [PMID: 28912946]
  11. Biomaterials. 2013 Jan;34(2):413-21 [PMID: 23084553]
  12. Microbiol Rev. 1992 Sep;56(3):395-411 [PMID: 1406489]
  13. Tissue Eng Part B Rev. 2010 Aug;16(4):371-83 [PMID: 20121414]
  14. Int Urogynecol J. 2011 Apr;22(4):401-5 [PMID: 20938644]
  15. J Immunol. 1993 Sep 15;151(6):3261-6 [PMID: 8376778]
  16. J Urol. 1997 Jan;157(1):61-4 [PMID: 8976216]
  17. Sci Rep. 2016 May 18;6:26083 [PMID: 27188581]
  18. Pharmazie. 2010 Jan;65(1):19-24 [PMID: 20187574]
  19. Sci Rep. 2017 Nov 21;7(1):15892 [PMID: 29162939]
  20. J Urol. 1993 Apr;149(4):716-8 [PMID: 8455229]
  21. Endothelium. 2001;8(2):107-16 [PMID: 11572474]
  22. J Control Release. 2011 Oct 30;155(2):193-9 [PMID: 21513749]
  23. Nat Protoc. 2010 Jun;5(6):993-1004 [PMID: 20448545]
  24. J Urol. 1998 Oct;160(4):1282-4 [PMID: 9751336]
  25. Macromol Biosci. 2015 May;15(5):682-90 [PMID: 25641575]
  26. Ann Biomed Eng. 2015 Mar;43(3):657-80 [PMID: 25537688]
  27. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):996-1001 [PMID: 11792842]
  28. J Microbiol Biotechnol. 2009 Jun;19(6):616-21 [PMID: 19597321]
  29. J Bacteriol. 2008 Aug;190(15):5265-78 [PMID: 18539737]
  30. Acta Biomater. 2014 May;10(5):2076-85 [PMID: 24389319]
  31. Urology. 2007 Apr;69(4 Suppl):9-16 [PMID: 17462486]
  32. Int Braz J Urol. 2017 Jan-Feb;43(1):134-141 [PMID: 28124536]
  33. J Membr Biol. 1993 May;133(3):227-42 [PMID: 8331646]
  34. J Immunol. 2008 Aug 1;181(3):2103-10 [PMID: 18641349]
  35. Carbohydr Polym. 2015 Jan 22;115:325-33 [PMID: 25439901]
  36. Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):717-21 [PMID: 18097627]
  37. Int J Urol. 2014 Apr;21 Suppl 1:75-8 [PMID: 24807505]
  38. J Biomed Mater Res B Appl Biomater. 2021 Jun;109(6):864-876 [PMID: 33103826]
  39. PLoS One. 2013 Oct 17;8(10):e76779 [PMID: 24146927]
  40. Transl Androl Urol. 2015 Oct;4(5):563-571 [PMID: 26751576]
  41. Carbohydr Polym. 2014 Aug 8;108:239-46 [PMID: 24751270]
  42. Acta Biomater. 2015 Jun;19:66-75 [PMID: 25818949]
  43. J Urol. 1997 Sep;158(3 Pt 1):790-3 [PMID: 9258082]
  44. Anal Biochem. 1962 Oct;4:330-4 [PMID: 13971270]
  45. J Lab Autom. 2015 Apr;20(2):107-26 [PMID: 25586998]
  46. Eur Urol. 2007 Jun;51(6):1534-40; discussion 1540-1 [PMID: 17383810]
  47. Scand J Urol Nephrol. 2005;39(2):143-7 [PMID: 16032779]
  48. Ther Adv Urol. 2011 Feb;3(1):19-33 [PMID: 21789096]
  49. J Urol. 2015 May;193(5):1545-53 [PMID: 25623737]
  50. Can Urol Assoc J. 2014 Sep;8(9-10):E610-4 [PMID: 25295131]
  51. Nanomaterials (Basel). 2019 Sep 02;9(9): [PMID: 31480704]
  52. Urology. 2001 Jun;57(6 Suppl 1):47-55 [PMID: 11378050]
  53. Urology. 2007 Apr;69(4 Suppl):64-72 [PMID: 17462483]
  54. Biotechnol Lett. 2007 Jan;29(1):17-25 [PMID: 17091377]
  55. Can J Microbiol. 1998 May;44(5):423-9 [PMID: 9699297]
  56. Int Urogynecol J. 2012 Sep;23(9):1187-92 [PMID: 22569687]
  57. Colloids Surf B Biointerfaces. 2017 Nov 1;159:30-38 [PMID: 28779638]
  58. FEBS Lett. 1999 Jun 25;453(3):283-7 [PMID: 10405161]
  59. Urology. 2007 Apr;69(4 Suppl):17-23 [PMID: 17462475]
  60. J Urol. 1993 Mar;149(3):465-9 [PMID: 8437248]
  61. J Mater Chem B. 2017 Mar 28;5(12):2355-2363 [PMID: 32263627]
  62. J Urol. 2001 Jun;165(6 Pt 1):2068-74 [PMID: 11371930]
  63. Int J Urol. 2013 Feb;20(2):203-7 [PMID: 22925498]

Grants

  1. 13/RC/2073/Science Foundation Ireland

MeSH Term

Cell Line
Chondroitin Sulfates
Cystitis, Interstitial
Humans
Hyaluronic Acid
Urothelium

Chemicals

Hyaluronic Acid
Chondroitin Sulfates
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Created with Highcharts 10.0.0permeabilitybarrierHAcystitishyaluronicacidbiphasicdiseaseinflammationsysteminterstitialICbladderurothelialeffectscellmetabolismeffectInterstitialprogressivecharacterizedincreasedabdominalpainconsensusetiologybelievedrestoringurinarysolutesGAGurotheliuminterruptprogressionCurrentlyseveraltreatmentoptionsincludeintravesicaldeliveryand/orchondroitinsulfatesolutionscatheterrestoreshownlimitedsuccesspreclinicalclinicaltrialsHereinreportfirsttimesuccessfulengineeringcharacterizationdevelopedcombiningcross-linkednaïvesolutiondecreasevitromodelcross-linkingperformed4-arm-polyethyeleneaminechemistryformulationstestedviscoelasticpropertiesinflammatorymarkersstudydemonstratestherapeuticdifferentratiosreportsabilityincreasedecreasingalterationrespectrelativecontrolsRestoringusingtherapymaypromisingapproachhighmolecularweightdispersionpotentialtherapeutics

Similar Articles

Cited By (4)